530057 — Vivanza Biosciences Income Statement
0.000.00%
Last trade - 00:00- IN₹70.80m
- IN₹172.07m
- IN₹1.16bn
Annual income statement for Vivanza Biosciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 104 | 178 | 278 | 74.2 | 1,159 |
| Cost of Revenue | |||||
| Gross Profit | 7.47 | 13 | 18.8 | 6.03 | 14.8 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 105 | 171 | 268 | 78 | 1,152 |
| Operating Profit | -0.898 | 6.6 | 10.5 | -3.76 | 7.11 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 3.33 | 7.17 | 6.95 | -6.66 | 5.44 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 3.33 | 5.98 | 5.47 | -6.74 | 3.94 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 3.33 | 5.98 | 5.47 | -6.74 | 3.94 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 3.33 | 5.98 | 5.47 | -6.74 | 3.94 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.083 | 0.15 | 0.14 | -0.169 | 0.1 |